Prelude Therapeutics
PRLD
39 hedge funds and large institutions have $1,000M invested in Prelude Therapeutics in 2020 Q3 according to their latest regulatory filings, with 39 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
78.48% more ownership
Funds ownership: 0% → 78.48% (+78%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$440M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$286M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$88.3M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$21.2M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$20.5M |
Top Sellers
PRLD Hedge Fund Activity: Q3 2020 in Review
39 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2020, worth a combined $1,000M.
Buyers outnumbered sellers: 39 funds opened new PRLD positions and 0 closed out — a net gain of 39 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $440M.
- 39 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $1,000M of Prelude Therapeutics stock for Q3 2020.
- 39 funds opened new Prelude Therapeutics positions in Q3 2020 and 0 closed out, a net change of +39 holders.
- The largest Prelude Therapeutics buyer in Q3 2020 was OrbiMed, an estimated $440M added.
Based on aggregated 13F filings for Q3 2020.